BRPI0411455A - composto, formulação farmacêutica, método de tratamento ou prevenção de distúrbios de lipìdeo, uso de um composto, método de tratamento de diabetes do tipo 2, e, composição farmacêutica - Google Patents

composto, formulação farmacêutica, método de tratamento ou prevenção de distúrbios de lipìdeo, uso de um composto, método de tratamento de diabetes do tipo 2, e, composição farmacêutica

Info

Publication number
BRPI0411455A
BRPI0411455A BRPI0411455-8A BRPI0411455A BRPI0411455A BR PI0411455 A BRPI0411455 A BR PI0411455A BR PI0411455 A BRPI0411455 A BR PI0411455A BR PI0411455 A BRPI0411455 A BR PI0411455A
Authority
BR
Brazil
Prior art keywords
compound
type
treating
pharmaceutical composition
lipid disorders
Prior art date
Application number
BRPI0411455-8A
Other languages
English (en)
Inventor
Ralf Ragnar
Erica Stahle
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BRPI0411455A publication Critical patent/BRPI0411455A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/18—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides
    • C07C235/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"COMPOSTO, FORMULAçãO FARMACêUTICA, MéTODO DE TRATAMENTO OU PREVENçãO DE DISTúRBIOS DE LIPìDEO, USO DE UM COMPOSTO, MéTODO DE TRATAMENTO DE DIABETES DO TIPO 25 E, COMPOSIçãO FARMACêUTICA". Um sal de cálcio ou de magnésio do ácído (2S)-2-etóxi-3-(4-{2-¢hexil (2-feniletil)amino!-2-oxoetóxi} fenil propanóico.
BRPI0411455-8A 2003-06-18 2004-06-16 composto, formulação farmacêutica, método de tratamento ou prevenção de distúrbios de lipìdeo, uso de um composto, método de tratamento de diabetes do tipo 2, e, composição farmacêutica BRPI0411455A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0314136.3A GB0314136D0 (en) 2003-06-18 2003-06-18 Therapeutic agents
PCT/SE2004/000965 WO2004110985A1 (en) 2003-06-18 2004-06-16 Pharmaceutically useful salts of carboxylic acid derivates

Publications (1)

Publication Number Publication Date
BRPI0411455A true BRPI0411455A (pt) 2006-07-18

Family

ID=27636795

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0411455-8A BRPI0411455A (pt) 2003-06-18 2004-06-16 composto, formulação farmacêutica, método de tratamento ou prevenção de distúrbios de lipìdeo, uso de um composto, método de tratamento de diabetes do tipo 2, e, composição farmacêutica

Country Status (21)

Country Link
US (1) US20060194879A1 (pt)
EP (1) EP1638921A1 (pt)
JP (1) JP3836498B1 (pt)
KR (1) KR20060017646A (pt)
CN (1) CN1805922A (pt)
AR (1) AR044802A1 (pt)
AU (1) AU2004247611A1 (pt)
BR (1) BRPI0411455A (pt)
CA (1) CA2527608A1 (pt)
CO (1) CO5650229A2 (pt)
GB (1) GB0314136D0 (pt)
IL (1) IL172168A0 (pt)
IS (1) IS8232A (pt)
MX (1) MXPA05013713A (pt)
NO (1) NO20055923L (pt)
RU (1) RU2005138369A (pt)
SA (1) SA04250170B1 (pt)
TW (1) TW200503678A (pt)
UY (1) UY28371A1 (pt)
WO (1) WO2004110985A1 (pt)
ZA (1) ZA200510199B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0229931D0 (en) * 2002-12-21 2003-01-29 Astrazeneca Ab Therapeutic agents
SE0104334D0 (sv) * 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
GB0314079D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
SE0104333D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
WO2004000790A1 (en) 2002-06-20 2003-12-31 Astrazeneca Ab Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance
WO2007004957A1 (en) * 2005-07-05 2007-01-11 Astrazeneca Ab Novel crystalline form
AR055073A1 (es) * 2005-07-11 2007-08-01 Astrazeneca Ab Agentes terapeuticos
FR2903985B1 (fr) 2006-07-24 2008-09-05 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
FR2904316B1 (fr) 2006-07-31 2008-09-05 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique.
UY30648A1 (es) * 2006-10-20 2008-05-02 Janssen Pharmaceutica Nv Formas salinas de compuestos de benzotienilo sustituido

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL351898A1 (en) * 1999-04-06 2003-06-30 Sankyo Co O-substituted derivatives of carboxylic acids
SE0104334D0 (sv) * 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents

Also Published As

Publication number Publication date
UY28371A1 (es) 2005-01-31
CO5650229A2 (es) 2006-06-30
WO2004110985A1 (en) 2004-12-23
CN1805922A (zh) 2006-07-19
CA2527608A1 (en) 2004-12-23
JP3836498B1 (ja) 2006-10-25
GB0314136D0 (en) 2003-07-23
EP1638921A1 (en) 2006-03-29
KR20060017646A (ko) 2006-02-24
IL172168A0 (en) 2009-02-11
IS8232A (is) 2006-01-13
JP2006527767A (ja) 2006-12-07
TW200503678A (en) 2005-02-01
RU2005138369A (ru) 2007-07-27
ZA200510199B (en) 2006-12-27
AU2004247611A1 (en) 2004-12-23
AR044802A1 (es) 2005-10-05
MXPA05013713A (es) 2006-06-27
NO20055923L (no) 2006-01-06
US20060194879A1 (en) 2006-08-31
SA04250170B1 (ar) 2007-10-29

Similar Documents

Publication Publication Date Title
EA200501715A1 (ru) Замещённые аминокарбоновые кислоты в качестве ингибиторов протеинтирозинфосфатазы-1в
BRPI0512213A (pt) método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto
DE69613365D1 (de) Ester der 5-aminolevulinsäure als mittel zur photosensibilisierung in der chemotherapie
BRPI0409916A (pt) ácidos carboxìlicos substituìdos com fenila
ATE443043T1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
ATE384526T1 (de) N-(((((1,3-thiazol-2- yl)amino)carbonyl)phenyl)sulphonyl)phenylalanin derivate und verwandte verbindungen zur behandlung von diabetes
BRPI0512220A (pt) método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto
DK1780197T3 (da) 5-Substituerede 2-phenylamino-benzamider som MEK-inhibitorer
BR0116370A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente.
HUP0300684A2 (hu) Szomatosztatin analógok, azokat tartalmazó gyógyszerkészítmények és alkalmazásuk
BRPI0519195A2 (pt) composiÇço de cuidado oral, e, mÉtodo para prevenir ou tratar cÁrie dental em um indivÍduo humano ou animal
BR0115427A (pt) Composto, composição farmacêutica, métodos para inibir a liberação de peptìdeo beta-amilóide e/ou sua sìntese, para tratar a doença de alzheimer, e para prevenir a doença e o progresso da doença de alzheimer, e, uso de um composto
ATE496048T1 (de) Phenylcarboxamidverbindungen zur schmerzbehandlung
BRPI0410316A (pt) composto, composição farmacêutica, uso dos compostos, e, método de tratamento de distúrbios mediados por vr1 e para o tratamento de distúrbios de dores
BRPI0515261A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso do composto quìmico ou de qualquer um de seus isÈmeros ou de qualquer mistura de seus isÈmeros, ou um sal farmaceuticamente aceitável do mesmo, e, método para o tratamento, a prevenção ou o alìvio de uma doença ou de um distúrbio ou de uma condição de um corpo de animal vivo
BRPI0612840A8 (pt) Composição de ração para prevenir ou tratar doença renal, métodos para prevenir ou tratar doença renal e para produzir uma composição de ração, kit, e, meio para comunicar informação ou instruções
BRPI0411455A (pt) composto, formulação farmacêutica, método de tratamento ou prevenção de distúrbios de lipìdeo, uso de um composto, método de tratamento de diabetes do tipo 2, e, composição farmacêutica
WO2006035157A3 (fr) Composes derives de n- (benzyl) phenylacetamide substitues , preparation et utilisations comme ligands des ppar dans le traitement des dereglements lipidiques et/ou glucidiques
DE602004002394D1 (de) (3-ä3-'(2,4-BIS-TRIFLUORMETHYL-BENZYL)-(5-ETHYL-PYRIMIDIN-2-YL)-AMINOÜ-PROPOXYü-PHENYL)-ESSIGSÄURE UND VERWANDTE VERBINDUNGEN ALS MODULATOREN VON PPARS UND VERFAHREN ZUR BEHANDLUNG VON STOFFWECHSELSTÖRUNGEN
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
BRPI0415781A (pt) método para o tratamento de diabetes em um paciente e kit farmacêutico
EE200400031A (et) Biokeemiliste ühendite kompositsioon, selle kasutamine maatriks-metalloproteinaaside pärssimiseks ning seda sisaldav ravimpreparaat
RU95112456A (ru) Производные n-(3-пиперидинилкарбонил)-бета-аланина в качестве антагонистов фактора активации тромбоцитов (фат), способ получения, фармацевтическая композиция и способ лечения
ATE365159T1 (de) 3-(2-phenyl-oxazol-4- ylmethoxy)- cyclohexylmethoxy -essigsäure derivate und verwandte verbindungen als ppar modulatoren zur behandlung von typ 2 diabetes und atherosklerose
BRPI0519152A2 (pt) composto ou um sal ou derivado Éster farmaceuticamente aceitÁvel do mesmo, formulaÇço farmacÊutica, formulaÇÕes para tratar osteoporose e psorÍase, uso de um composto ou de um sal farmaceuticamente aceitÁvel do mesmo, e, composiÇço farmacÊutica

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.